Imagion Biosystems

Imagion Biosystems FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Imagion Biosystems (IBX.AX) as of Oct 18, 2026 is 93.83 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 61.47 % — a change of 52.64% (higher).

FCF Conversion

93.83 %

YoY

52.64%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Imagion Biosystems is 2025 93.83 % . FCF Conversion Rate (FCF/EBITDA) of Imagion Biosystems was 2024 61.47 % . It decreases by 52.64% higher compared to the previous year.

The Imagion Biosystems FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
98.44 AUD
Jan 1, 2019
122.20 AUD
Jan 1, 2020
86.33 AUD
Jan 1, 2021
87.76 AUD
Jan 1, 2022
87.48 AUD
Jan 1, 2023
68.19 AUD
Jan 1, 2024
61.47 AUD
Jan 1, 2025
93.83 AUD
The Imagion Biosystems FCF Conversion history
YEARFCF ConversionYoY
93.83 %+52.64%
61.47 %-9.86%
68.19 %-22.05%
87.48 %-0.31%
87.76 %+1.65%
86.33 %-29.35%
122.20 %+24.13%
98.44 %+4.44%
94.26 %+53.11%
61.56 %-40.85%
104.09 %+5.78%
98.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd is a Melbourne-based company operating in the Health Care sector. It focuses on research and development of non-radioactive diagnostic imaging technology. The company went public on June 22, 2017. Its MagSense technology uses bio-safe magnetic nanoparticles for cancer detection, specifically formulated for breast, prostate, and ovarian cancers. MagSense nanoparticles are injectable solutions tailored to each cancer type. The firm also develops PrecisionMRX nanoparticles for magnetic relaxometry, available in various coatings including dextran, mPEG, oleic acid, and carboxylic acid functionalized. Imagion Biosystems operates through a Research and Development segment. Imagion Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imagion Biosystems stock

FCF Conversion Rate (FCF/EBITDA) of Imagion Biosystems is 93.83 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Imagion Biosystems changed from 61.47 % to 93.83 %, representing a 52.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Imagion Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Imagion Biosystems

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Imagion Biosystems